You have no items in your cart.
Zejula Now Available in UK as Maintenance Therapy for Advanced Ovarian Cancer

The National Institute of Health and Care Excellence (NICE) has recommended the use of Zejula (niraparib) as a maintenance therapy for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The medication will be available through the Cancer Drugs Fund (CDF), a funding program that seeks to increase access to promising cancer medicines in England for patients with or without BRCA-mutated tumors who are responding to their initial round of platinum-based chemotherapy. NICE’s recommendation might…